Pasar al contenido principal

AISLAMIENTO Y CARACTERIZACION MOLECULAR DE CELULAS TUMORALES CIRCULANTES (CTCS): POTENCIALES BIOMARCADORES EN CARCINOMA HEPATOCELULAR

PI21/00714

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Centro realización INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma

  • Pinato, David James|||0000-0002-3529-0103
  • Kaneko, Takahiro
  • D'Alessio, Antonio
  • Forner, Alejandro|||0000-0002-9014-4950
  • Fessas, Petros|||0000-0002-7472-8913
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Giannini, Edoardo G.
  • Grillo, Federica
  • Díaz, Alba|||0000-0002-0456-7085
  • Mauri, Francesco A.
  • Fulgenzi, Claudia A.M.
  • Dalla Pria, Alessia
  • Goldin, Robert D.
  • Pieri, Giulia
  • Toniutto, Pierluigi|||0000-0002-2566-3041
  • Avellini, Claudio
  • Plaz Torres, Maria Corina
  • Akarca, Ayse U.
  • Marafioti, Teresa
  • Bhoori, Sherrie
  • Miró, José M.|||0000-0001-8057-7755
  • Bower, Mark
  • Bräu, Norbert
  • Mazzaferro, Vincenzo|||0000-0002-4013-8085
HIV-seropositivity shortens survival in patients with hepatocellular carcinoma (HCC). Although risk factors for HCC including HCV infection can influence T cell phenotype, it is unknown whether HIV can influence functional characteristics of the T cell infiltrate. From the Liver Cancer in HIV biorepository, we derived 129 samples of transplanted (76%) or resected (20%) HCC in eight European and North American centres. We profiled intra- and peritumoural tissue to evaluate regulatory CD4+/FOXP3+ and immune-exhausted CD8+/PD1+ T cells in HIV+ (n = 66) and HIV- (n = 63) samples. We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples evaluated in relationship with HIV status. We correlated immunopathologic features with patients' characteristics including markers of HIV infection. Of the 66 HIV+ patients, 83% were HCV coinfected with an undetectable HIV viral load (51%) and a median blood CD4+ cell count of 430 cells/mm 3 (range 15-908). Patients who were HIV+ were compared with HIV- controls with similar staging characteristics including Barcelona Clinic Liver Cancer (BCLC) stage A-B (86% vs. 83%, p = 0.16), <3 nodules (90% vs. 83%, p = 0.3) and median alpha-foetoprotein values (10.9 vs. 12.8 ng/ml, p = 0.72). HIV+ samples had higher PD-L1 expression rates in tumour tissue (51% vs. 8% p <0.0001) and displayed denser intratumoural CD4+/FOXP3+ (p <0.0001), CD8+/PD1+ (p <0.0001), with lower total peritumoural CD4+ (p <0.0001) and higher peritumoural CD8+/PD1+ (p <0.0001). Gene set analysis revealed HIV+ cases to have evidence of dysregulated adaptive and innate immunity. Tumour-infiltrating lymphocyte clonality was not influenced by HIV status. HIV-associated HCC harbours a profoundly immune-exhausted tumour microenvironment, warranting prospective testing of immunotherapy in this treatment-deprived patient population. Hepatocellular carcinoma is a non-AIDS defining malignancy characterised by poor survival. The programmed cell death (PD-1) pathway governs antiviral and anticancer immune exhaustion and is a therapeutic target in HCC. This study highlights how HIV infection is associated with significantly higher PD-L1 expression in HCC cells and in the surrounding microenvironment, leading to changes in cytotoxic and regulatory T cell function and dysregulation of proinflammatory pathways. Taken together, our results suggest dysfunctional T cell immunity as a mechanism of worse outcome in these patients and suggest clinical testing of checkpoint inhibitors in HIV-associated HCC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evolving epidemiology of HCC in Spain

  • Sala Llinas, Margarita|||0000-0003-4879-1780
  • Pascual, Sonia|||0000-0002-4265-5019
  • Rota Roca, Maria Rosa
  • Matilla, Ana María
  • Campos, Marta
  • Delgado, Manuel
  • Ferrer, María Teresa
  • Montero, José Luís
  • González Santiago, Jesús M.|||0000-0003-4667-4492
  • Guerrero, Antonio
  • Aracil, Carlos|||0000-0002-8228-9041
  • Rodríguez Lope, Carlos|||0000-0002-6713-8800
  • Romero-Gutiérrez, Marta
  • Sogbe, Miguel|||0000-0002-2846-7812
  • Vázquez Rodríguez, Sergio|||0000-0001-6108-9449
  • Fuentes Olmo, Javier|||0000-0001-8637-510X
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Cortés-García, Luis|||0000-0003-3164-2703
  • Vallejo-Senra, N.
  • Rendón, Paloma|||0000-0002-6521-3766
  • Clos, Ariadna|||0000-0002-6414-2097
  • Díaz-Bethencourt, D.
  • García Sánchez, Araceli
  • Quiñones Castro, Raisa|||0000-0003-2446-9068
  • Bustamante, Javier|||0000-0002-5280-3038
  • Perelló, Christie|||0000-0003-0234-2330
  • Urquijo Ponce, J.J.
  • Andreu Serra, Hernán
  • Llamoza-Torres, Camilo J.|||0000-0001-8072-9413
  • Montoliu, Silvia|||0000-0002-3041-578X
  • Fernández Marcos, Cristina
  • Guiberteau, A.
  • Hernandez-Guerra, Manuel|||0000-0002-3478-9981
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Fernández-López, A.M.
  • Valer López-Fando, M.P.
  • Gutiérrez-García, M.L.
  • Hernáez-Alsina, T.|||0000-0002-3734-2448
  • Coll, Susanna|||0000-0002-0395-9685
  • Cuyàs, Berta|||0000-0001-9988-7163
  • Morillas, M.J.
  • Rebolledo Olmedo, Susana
  • Fernández Bermejo, Miguel
  • Roget, Mercè
  • Calvo Ramos, Irina
  • Pacheco del Río, G.
  • Rifà, Raimon|||0000-0003-1911-3681
  • Conde Gacho, Pilar
  • Llorente Barrio, Mónica|||0000-0003-0267-989X
  • Gómez-Rubio, M.
  • Peñas, Irene
  • Serra Matamala, Isabel|||0000-0002-5694-9325
  • Cachero, Alba|||0000-0002-0010-4534
  • Reig, María|||0000-0002-5711-9534
  • Giráldez-Gallego, Álvaro|||0000-0001-6849-9272
  • Guerrero Misas, Marta
  • Segarra, J.X.|||0000-0002-7222-5191
  • Lledó, J.L.
  • Díaz-González, Álvaro|||0000-0003-3610-2263
  • Delgado, Carolina|||0000-0002-0808-4494
  • Iñarrairaegui, M.
  • Rodríguez-González, M.M.
  • Lázaro, M.
  • Bermúdez-Ramos, María|||0000-0002-5516-3902
  • Lué, A.|||0000-0002-9672-6038
  • Molina, E.
  • Macías-Rodríguez, M.A.|||0000-0003-2634-6125
  • Rodríguez, Manuel|||0000-0001-5763-7668
  • Chiminazzo, V.
  • Varela Calvo, Maria|||0000-0003-4288-2593
Background & Aims: The epidemiological landscape of hepatocellular carcinoma (HCC) in Europe is evolving. This study aims to provide an updated description of the current epidemiology of liver cancer in Spain. Methods: This multicenter prospective study collected demographic and clinical data on primary liver cancer between October 2022 and January 2023. We conducted descriptive and comparative analyses with data collected in 2008 and 2014. Results: Of the 767 cases of primary liver cancer collected from 52 centers, 91% were diagnosed as HCC. The majority of patients were male (83.3%), average age 68 years, 80.7% had cirrhosis. The primary causes were alcohol (29.9% alone, 55% combined with other etiologies), liver disease related to metabolic syndrome (LDrMS, 23%) and hepatitis C (17.3%). Treatments included ablation (15.7%), systemic therapy (14.7%), and chemoembolization (14.6%). Data from 29 centers (n = 1,351) across three registries revealed a significant increase in LDrMS (from 4.9% to 24%) and HCC in non-cirrhotic livers (from 4.2% to 7.9%). Meanwhile, hepatitis C decreased sharply (from 43% to 17.5%). Alcohol-related cases remained stable. There was a slight increase in male patients and hypertension, diabetes, and obesity. Patients with cirrhosis diagnosed outside of screening programs presented with larger tumors and more advanced disease. This led to fewer evaluations for curative treatments. Conclusions: Alcohol accounts for 30% of HCC cases and is the main etiology. The registry shows a decrease in hepatitis C-related HCC, an increase in LDrMS and HCC in non-cirrhotic livers. Surveillance was implemented in ∼80% of the recommended population. There is a need for improved screening and prevention strategies, particularly for alcohol abuse and LDrMS, to enhance HCC management. Impact and implications: Our study showcases the involvement of numerous reference centers across Spain and examines over 1,300 patients to track the changing epidemiology of hepatocellular carcinoma (HCC) over 14 years. In patients with known liver cirrhosis, more than 80% of HCC diagnoses were made through screening leading to early-stage identification and curative treatment opportunities. Notably, there has been a shift in HCC etiology within the registries from hepatitis C to liver disease related to metabolic syndrome, with an increase in cases without cirrhosis. Findings indicate a need for the prevention and early detection of HCC, particularly focusing on alcohol and liver disease related to metabolic syndrome, along with greater involvement of health authorities, to improve the participation of at-risk patients in screening programs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical Trial, Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)

  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Matilla, Ana
  • Lledó-Navarro, José Luis|||0000-0001-7973-3503
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Varela Calvo, Maria|||0000-0003-4288-2593
  • Iñarrairaegui, Mercedes|||0000-0001-9180-4693
  • Perelló, Christie|||0000-0003-0234-2330
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Llarch, Neus|||0000-0003-3209-0453
  • Márquez, Laura
  • Guerrero, Antonio
  • Iserte, Gemma|||0000-0003-3908-8743
  • Castaño-García, Andrés|||0000-0002-7921-9026
  • Carrión, Laura
  • Fortuny, Marta
  • Rimola, Jordi|||0000-0002-1814-4198
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Domenech, Gema
  • Torres, Ferran|||0000-0002-7355-7913
  • Ríos, José|||0000-0002-0716-8784
  • Boix, Loreto|||0000-0002-6015-3901
  • Samper, Esther
  • Kateb, Àngels
  • Bruix, Jordi|||0000-0002-9826-0753
  • Reig, María|||0000-0002-5711-9534
BACKGROUND & AIMS: Highly effective second-line treatments for hepatocellular carcinoma remain an unmet need. The GOING investigator-initiated Phase I/IIa trial evaluated regorafenib plus nivolumab (add-on) in patients who progressed on sorafenib (Cohort-A) or discontinued atezolizumab-bevacizumab (Cohort-B). METHODS: Patients received regorafenib for two 28-day cycles, adding nivolumab in cycle 3, until unacceptable adverse events, symptomatic progression, withdrawal or death. Primary endpoint was safety. Secondary endpoints included overall survival, time to progression, post-progression survival, objective response rate and incidence of new-extrahepatic-spread. RESULTS: Of 85 patients screened, 67 were enrolled (75.5% BCLC-C). All experienced adverse events and 9% led to discontinuation. Severe treatment-related adverse events occurred in 28.4% overall, 32.1% in Cohort-A, and 14.3% in Cohort-B. Median overall survival was 20.0 (95% CI 11-37) months, with 40.6% survival at 36 months. In Cohort-A, median overall survival was 25 (95% CI 14-39) months with 45% survival at 36 months, while Cohort-B median overall survival was 8 (95% CI 4-NE) months with 28.6% survival at 24 months. Objective response rate was 16.4%; median time to progression and post-progression survival were 5 (95% CI 4-9) months and 14 (95% CI 8-33) months. Intrahepatic growth was the most common progression pattern, followed by new-extrahepatic-spread. CONCLUSIONS: The add-on strategy of regorafenib plus nivolumab in second-line had manageable safety and significant clinical activity with a noteworthy median overall survival of 20 months. Among those progressing on sorafenib, 45% were alive at 3 years. These findings support further evaluation with mechanism-guided trials after progression on immunotherapy. TRIAL REGISTRATION: EudraCT number: 2019-003108-10; https://www.clinicaltrialsregister.eu.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Harnessing Plasma Biomarkers to Predict Immunotherapy Outcomes in Hepatocellular Carcinoma: The Role of cfDNA, ctDNA, and Cytokines

  • Merino Casabiel, Xavier
  • Vargas Accarino, Elena
  • Higuera Urbano, Monica
  • Bermúdez-Ramos, Maria
  • Soriano, Agnès
  • Torrens Buscató, Maria
  • Pons, Mònica
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Minguez, Beatriz
Biomarkers; Hepatocellular carcinoma; Immunotherapy, Biomarcadors; Carcinoma hepatocel·lular; Immunoteràpia, Biomarcadores; Carcinoma hepatocelular; Inmunoterapia, Immunotherapy has improved survival in patients with advanced hepatocellular carcinoma (HCC); yet, objective radiological responses occur in only about 20% of cases, suggesting variable benefits. This study aimed to identify serologic markers predictive of response to immune checkpoint inhibitors (ICIs). A cohort of 38 advanced HCC patients receiving immunotherapy was prospectively analyzed. Levels of cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and cytokines were measured pre-treatment and three months post-treatment initiation. Genomic profiling of ctDNA was also conducted. Baseline levels of cfDNA and ctDNA effectively discriminated HCC patients based on their radiological response to ICIs. Additionally, individuals with pathologic mutations in the CDKN2A gene exhibited significantly reduced survival. Patients with progressive disease (PD) as their best radiological response had significantly fewer copy number variations (CNVs) than those with a radiological response. Furthermore, levels of IL10, PD1, and TGFβ assessed after three months of treatment showed significant variations correlating with survival status. In conclusion, the analysis of cfDNA, ctDNA, and cytokines may improve treatment selection for HCC patients by predicting their expected response to immunotherapies., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI21/00714 and PI18/00961 to B.M. and co-funded by the European Union. E.V.-A. is a recipient of a predoctoral fellowship from Instituto de Salud Carlos III (ISCIII) (FI18/00027).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Evolving epidemiology of HCC in Spain

  • Sala Llinas, Margarita
  • Pascual, Sonia
  • Rota Roca, Maria Rosa
  • Matilla, Ana María
  • Campos, Marta
  • Delgado, Manuel
  • Minguez, Beatriz
  • Bermúdez-Ramos, Maria
Etiology; Liver cancer; Surveillance, Etiología; Cáncer de hígado; Vigilancia, Etiologia; Càncer de fetge; Vigilància, Background & Aims The epidemiological landscape of hepatocellular carcinoma (HCC) in Europe is evolving. This study aims to provide an updated description of the current epidemiology of liver cancer in Spain. Methods This multicenter prospective study collected demographic and clinical data on primary liver cancer between October 2022 and January 2023. We conducted descriptive and comparative analyses with data collected in 2008 and 2014. Results Of the 767 cases of primary liver cancer collected from 52 centers, 91% were diagnosed as HCC. The majority of patients were male (83.3%), average age 68 years, 80.7% had cirrhosis. The primary causes were alcohol (29.9% alone, 55% combined with other etiologies), liver disease related to metabolic syndrome (LDrMS, 23%) and hepatitis C (17.3%). Treatments included ablation (15.7%), systemic therapy (14.7%), and chemoembolization (14.6%). Data from 29 centers (n = 1,351) across three registries revealed a significant increase in LDrMS (from 4.9% to 24%) and HCC in non-cirrhotic livers (from 4.2% to 7.9%). Meanwhile, hepatitis C decreased sharply (from 43% to 17.5%). Alcohol-related cases remained stable. There was a slight increase in male patients and hypertension, diabetes, and obesity. Patients with cirrhosis diagnosed outside of screening programs presented with larger tumors and more advanced disease. This led to fewer evaluations for curative treatments. Conclusions Alcohol accounts for 30% of HCC cases and is the main etiology. The registry shows a decrease in hepatitis C-related HCC, an increase in LDrMS and HCC in non-cirrhotic livers. Surveillance was implemented in ∼80% of the recommended population. There is a need for improved screening and prevention strategies, particularly for alcohol abuse and LDrMS, to enhance HCC management. Impact and implications Our study showcases the involvement of numerous reference centers across Spain and examines over 1,300 patients to track the changing epidemiology of hepatocellular carcinoma (HCC) over 14 years. In patients with known liver cirrhosis, more than 80% of HCC diagnoses were made through screening leading to early-stage identification and curative treatment opportunities. Notably, there has been a shift in HCC etiology within the registries from hepatitis C to liver disease related to metabolic syndrome, with an increase in cases without cirrhosis. Findings indicate a need for the prevention and early detection of HCC, particularly focusing on alcohol and liver disease related to metabolic syndrome, along with greater involvement of health authorities, to improve the participation of at-risk patients in screening programs., The Spanish Association for the Study of the Liver (AEEH) has supported the design of the database in the online digital platform (REDCap®) and the storage in an electronic file (https://aeeh.es/politica-de-privacidad/). Elena Avanzas, Ph.D, expert medical writer has reviewed all the content to ensure that the grammar and style sound natural in British English. BM received competitive grants from Instituto de Salud Carlos III (grant numbers PI18/00961 and PI21/00714) cofounded by the EU and a research grant from Laboratorios Viñas S.L. MR received grant support from Instituto de Salud Carlos III (PI18/0358 and PI22/01427), from Centro de Investigación Biomédica en Red - CIBER (Immune4Al, S2300092_3) and from the Spanish Association Against Cancer (AECC, PRYCO234831).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Impact of zinc on hepatocellular carcinoma cell behavior and metallothionein expression: Insights from preclinical models

  • Torrens Buscató, Maria
  • Bermúdez-Ramos, Maria
  • Soriano, Agnès
  • Higuera Urbano, Monica
  • Vargas-Accarino, Elena
  • Salcedo, Maria-Teresa
  • Minguez, Beatriz
Carcinoma hepatocel·lular; Zinc; Biomarcador, Hepatocellular carcinoma; Zinc; Biomarker, Carcinoma hepatocelular; Zinc; Biomarcador, Background Zinc (Zn) is an essential trace element involved in a wide variety of cellular processes and is vital for optimal liver function. Our objective was to elucidate the potential therapeutic role of Zn in hepatocellular carcinoma (HCC), the third leading cause of cancer-related death and the first cause of death in patients with cirrhosis. Methods The impact of Zn supplementation on proliferation, invasion, migration, cell cycle, and apoptosis was conducted on four HCC cell lines as well as in a xenograft mouse model of HCC from which tumor gene expression profiles were also analyzed. Gene deregulation and protein expression were validated in human HCC tissues. Finally, Zn and MT1 (Metallothionein 1) levels were quantified in plasma from patients with HCC. Results Zn supplementation significantly modulated proliferation, invasion, and migration in HCC cell lines and induced apoptosis in a dose-dependent manner. Although Zn did not exhibit a significant increase in survival, Zn supplementation significantly altered the expression of MT genes. Specifically, MT1G and MT1H expression were notably suppressed in HCC tissues from mice and these results were validated in human HCC samples. Overall, gene and protein MTs expression was significantly lower in HCC areas compared to adjacent liver tissue and plasma Zn levels exhibited substantial variation across different stages of the liver disease. Conclusion Zn supplementation influences key cellular behaviors in a dose-dependent manner and upregulates the expression of MT family genes, which may have tumor-suppressive properties, in vitro an in vivo models. Future research should investigate the prognostic implications of Zn supplementation as part of a comprehensive therapeutic strategy for HCC patients., This work has been funded by a research grant from Laboratorios Viñas. BM is supported by competitive funding by Instituto de Salud Carlos III (ISCIII) (PI18/00961 and PI21/00714) and co-funded by the European Union.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management

  • Vargas Accarino, Elena
  • Torrens Buscató, Maria Margarita
  • Salcedo Allende, Maria Teresa
  • Martínez Campreciós, Joan
  • Torres Pérez, Gloria
  • Bermúdez Ramos, María
  • Bilbao Aguirre, Itxarone Izaskun
  • Guerrero Murillo, Mercedes
  • Serres Créixams, Xavier
  • Merino Casabiel, Xavier
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Minguez Rosique, Beatriz
  • Gregori Font, Josep
  • Higuera Urbano, Monica
Biomarkers; cfDNA; Liquid biopsy, Biomarcadores; cfDNA; Biopsia líquida, Biomarcadors; cfDNA; Biòpsia líquida, Background: Cell-free DNA (cfDNA) concentrations have been described to be inversely correlated with prognosis in cancer. Mutations in HCC-associated driver genes in cfDNA have been reported, but their relation with patient’s outcome has not been described. Our aim was to elucidate whether mutations found in cfDNA could be representative from those present in HCC tissue, providing the rationale to use the cfDNA to monitor HCC. Methods: Tumoral tissue, paired nontumor adjacent tissue and blood samples were collected from 30 HCC patients undergoing curative therapies. Deep sequencing targeting HCC driver genes was performed. Results: Patients with more than 2 ng/µL of cfDNA at diagnosis had higher mortality (mean OS 24.6 vs. 31.87 months, p = 0.01) (AUC = 0.782). Subjects who died during follow-up, had a significantly higher number of mutated genes (p = 0.015) and number of mutations (p = 0.015) on cfDNA. Number of mutated genes (p = 0.001), detected mutations (p = 0.001) in cfDNA and ratio (number of mutations/cfDNA) (p = 0.003) were significantly associated with recurrence. However, patients with a ratio (number of mutations/cfDNA) above 6 (long-rank p = 0.0003) presented a higher risk of recurrence than those with a ratio under 6. Detection of more than four mutations in cfDNA correlated with higher risk of death (long-rank p = 0.042). Conclusions: In summary, cfDNA and detection of prevalent HCC mutations could have prognostic implications in early-stage HCC patients, This research was funded by Instituto de Salud Carlos III (ISCIII) (PI18/00961) and (PI21/00714) to B.M. PI19/00301 by Instituto de Salud Carlos III (ISCIII) and Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297 to J.Q., E.V.-A. is a recipient of a predoctoral fellowship from Instituto de Salud Carlos III (ISCIII) (FI18/00027).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management

  • Higuera, Mónica|||0000-0002-3999-9603
  • Vargas-Accarino, Elena|||0000-0002-2521-0368
  • Torrens, Maria|||0000-0003-3479-0066
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Martínez-Campreciós, Joan|||0000-0002-8899-8447
  • Torres, Gloria
  • Bermúdez-Ramos, María|||0000-0002-5516-3902
  • Bilbao, Itxarone|||0000-0002-7389-395X
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Serres Creixams, Xavier|||0000-0001-8642-467X
  • Merino, Xavier|||0000-0002-1985-9363
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Quer, Josep|||0000-0003-0014-084X
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
In this unicentric prospective study, we analyzed the most prevalent mutations in HCC (TERT promoter, TP53, CTNNB1, AXIN1 and ARID1A) in plasma cfDNA by next-generation sequencing, aiming to elucidate their value as prognostic noninvasive biomarkers. Total cfDNA (cut-off value 2 ng/µL), number of mutated genes and number of detectable mutations on cfDNA were significantly related to mortality. Number of mutated genes and number of detected mutations in cfDNA and the ratio between number of mutations and total amount of cfDNA were also significantly associated with recurrence. Detection of more than four mutations in cfDNA correlated with a higher risk of death. Dynamic changes in cfDNA mutations were detected prior to radiological detection of HCC recurrence. We believe that these results support the proof of principle and launching of validation studies to confirm that total cfDNA and detection of prevalent HCC mutations could have prognostic implications in early-stage HCC patients. Background: Cell-free DNA (cfDNA) concentrations have been described to be inversely correlated with prognosis in cancer. Mutations in HCC-associated driver genes in cfDNA have been reported, but their relation with patient's outcome has not been described. Our aim was to elucidate whether mutations found in cfDNA could be representative from those present in HCC tissue, providing the rationale to use the cfDNA to monitor HCC. Methods: Tumoral tissue, paired nontumor adjacent tissue and blood samples were collected from 30 HCC patients undergoing curative therapies. Deep sequencing targeting HCC driver genes was performed. Results: Patients with more than 2 ng/µL of cfDNA at diagnosis had higher mortality (mean OS 24.6 vs. 31.87 months, p = 0.01) (AUC = 0.782). Subjects who died during follow-up, had a significantly higher number of mutated genes (p = 0.015) and number of mutations (p = 0.015) on cfDNA. Number of mutated genes (p = 0.001), detected mutations (p = 0.001) in cfDNA and ratio (number of mutations/cfDNA) (p = 0.003) were significantly associated with recurrence. However, patients with a ratio (number of mutations/cfDNA) above 6 (long-rank p = 0.0003) presented a higher risk of recurrence than those with a ratio under 6. Detection of more than four mutations in cfDNA correlated with higher risk of death (long-rank p = 0.042). Conclusions: In summary, cfDNA and detection of prevalent HCC mutations could have prognostic implications in early-stage HCC patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma

  • Soria, Anna|||0000-0001-5671-8343
  • Calvo, Mariona|||0000-0001-6242-0500
  • Casas, Meritxell|||0000-0001-7227-7277
  • Vidales, Zara
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • Puigvehí, Marc|||0000-0002-3694-3241
  • Canillas, Lidia
  • Guardeño, Raquel
  • Gallego Moya, Adolfo|||0000-0002-8423-6787
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Horta Sangenís, Diana|||0000-0002-3675-1135
  • Clos, Ariadna|||0000-0002-6414-2097
  • Montoliu, Silvia|||0000-0002-3041-578X
  • Roget, Mercè
  • Reig, María|||0000-0002-5711-9534
  • Vergara, Mercedes|||0000-0002-6971-8657
The first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability in elderly patients under systemic treatment. The aims of this study were to characterize the profile of elderly patients treated with sorafenib, assess their survival and safety profile in order to extrapolate their eligibility for systemic treatment. Retrospective multicentre study of HCC patients aged ≥75 years old treated with sorafenib from January 2008 to December 2019. Demographic data, baseline characteristics, and variables related to HCC and sorafenib were recorded. Overall survival (OS) and safety were analyzed. The study included 206 patients from 11 hospitals, median age 77.9 years; 71.4% men and 62.6% stage Barcelona Clinic Liver Cancer- C (BCLC-C). The main causes of cirrhosis were hepatitis C (60.7%) and alcohol (14.7%). Most patients (84.5%) started with sorafenib 800mg and 15.5% at lower dosage. Arterial hypertension (AHT) (74.2 vs 62.2%; standardized mean differences (STD): 26) and baseline ECOG-PS.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Evolving epidemiology of HCC in Spain

  • Sala Llinas, Margarita
  • Pascual, Sonia
  • Rota Roca, Maria Rosa
  • Matilla, Ana María
  • Campos, Marta
  • Delgado, Manuel
  • Minguez, Beatriz
  • Bermúdez-Ramos, Maria
Etiology; Liver cancer; Surveillance, Etiología; Cáncer de hígado; Vigilancia, Etiologia; Càncer de fetge; Vigilància, Background & Aims The epidemiological landscape of hepatocellular carcinoma (HCC) in Europe is evolving. This study aims to provide an updated description of the current epidemiology of liver cancer in Spain. Methods This multicenter prospective study collected demographic and clinical data on primary liver cancer between October 2022 and January 2023. We conducted descriptive and comparative analyses with data collected in 2008 and 2014. Results Of the 767 cases of primary liver cancer collected from 52 centers, 91% were diagnosed as HCC. The majority of patients were male (83.3%), average age 68 years, 80.7% had cirrhosis. The primary causes were alcohol (29.9% alone, 55% combined with other etiologies), liver disease related to metabolic syndrome (LDrMS, 23%) and hepatitis C (17.3%). Treatments included ablation (15.7%), systemic therapy (14.7%), and chemoembolization (14.6%). Data from 29 centers (n = 1,351) across three registries revealed a significant increase in LDrMS (from 4.9% to 24%) and HCC in non-cirrhotic livers (from 4.2% to 7.9%). Meanwhile, hepatitis C decreased sharply (from 43% to 17.5%). Alcohol-related cases remained stable. There was a slight increase in male patients and hypertension, diabetes, and obesity. Patients with cirrhosis diagnosed outside of screening programs presented with larger tumors and more advanced disease. This led to fewer evaluations for curative treatments. Conclusions Alcohol accounts for 30% of HCC cases and is the main etiology. The registry shows a decrease in hepatitis C-related HCC, an increase in LDrMS and HCC in non-cirrhotic livers. Surveillance was implemented in ∼80% of the recommended population. There is a need for improved screening and prevention strategies, particularly for alcohol abuse and LDrMS, to enhance HCC management. Impact and implications Our study showcases the involvement of numerous reference centers across Spain and examines over 1,300 patients to track the changing epidemiology of hepatocellular carcinoma (HCC) over 14 years. In patients with known liver cirrhosis, more than 80% of HCC diagnoses were made through screening leading to early-stage identification and curative treatment opportunities. Notably, there has been a shift in HCC etiology within the registries from hepatitis C to liver disease related to metabolic syndrome, with an increase in cases without cirrhosis. Findings indicate a need for the prevention and early detection of HCC, particularly focusing on alcohol and liver disease related to metabolic syndrome, along with greater involvement of health authorities, to improve the participation of at-risk patients in screening programs., The Spanish Association for the Study of the Liver (AEEH) has supported the design of the database in the online digital platform (REDCap®) and the storage in an electronic file (https://aeeh.es/politica-de-privacidad/). Elena Avanzas, Ph.D, expert medical writer has reviewed all the content to ensure that the grammar and style sound natural in British English. BM received competitive grants from Instituto de Salud Carlos III (grant numbers PI18/00961 and PI21/00714) cofounded by the EU and a research grant from Laboratorios Viñas S.L. MR received grant support from Instituto de Salud Carlos III (PI18/0358 and PI22/01427), from Centro de Investigación Biomédica en Red - CIBER (Immune4Al, S2300092_3) and from the Spanish Association Against Cancer (AECC, PRYCO234831).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management

  • Vargas Accarino, Elena
  • Torrens Buscató, Maria Margarita
  • Salcedo Allende, Maria Teresa
  • Martínez Campreciós, Joan
  • Torres Pérez, Gloria
  • Bermúdez Ramos, María
  • Bilbao Aguirre, Itxarone Izaskun
  • Guerrero Murillo, Mercedes
  • Serres Créixams, Xavier
  • Merino Casabiel, Xavier
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Minguez Rosique, Beatriz
  • Gregori Font, Josep
  • Higuera Urbano, Monica
Biomarkers; cfDNA; Liquid biopsy, Biomarcadores; cfDNA; Biopsia líquida, Biomarcadors; cfDNA; Biòpsia líquida, Background: Cell-free DNA (cfDNA) concentrations have been described to be inversely correlated with prognosis in cancer. Mutations in HCC-associated driver genes in cfDNA have been reported, but their relation with patient’s outcome has not been described. Our aim was to elucidate whether mutations found in cfDNA could be representative from those present in HCC tissue, providing the rationale to use the cfDNA to monitor HCC. Methods: Tumoral tissue, paired nontumor adjacent tissue and blood samples were collected from 30 HCC patients undergoing curative therapies. Deep sequencing targeting HCC driver genes was performed. Results: Patients with more than 2 ng/µL of cfDNA at diagnosis had higher mortality (mean OS 24.6 vs. 31.87 months, p = 0.01) (AUC = 0.782). Subjects who died during follow-up, had a significantly higher number of mutated genes (p = 0.015) and number of mutations (p = 0.015) on cfDNA. Number of mutated genes (p = 0.001), detected mutations (p = 0.001) in cfDNA and ratio (number of mutations/cfDNA) (p = 0.003) were significantly associated with recurrence. However, patients with a ratio (number of mutations/cfDNA) above 6 (long-rank p = 0.0003) presented a higher risk of recurrence than those with a ratio under 6. Detection of more than four mutations in cfDNA correlated with higher risk of death (long-rank p = 0.042). Conclusions: In summary, cfDNA and detection of prevalent HCC mutations could have prognostic implications in early-stage HCC patients, This research was funded by Instituto de Salud Carlos III (ISCIII) (PI18/00961) and (PI21/00714) to B.M. PI19/00301 by Instituto de Salud Carlos III (ISCIII) and Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297 to J.Q., E.V.-A. is a recipient of a predoctoral fellowship from Instituto de Salud Carlos III (ISCIII) (FI18/00027).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Harnessing Plasma Biomarkers to Predict Immunotherapy Outcomes in Hepatocellular Carcinoma: The Role of cfDNA, ctDNA, and Cytokines

  • Merino Casabiel, Xavier
  • Vargas-Accarino, Elena
  • Higuera Urbano, Monica
  • Bermúdez-Ramos, Maria
  • Soriano, Agnès
  • Torrens Buscató, Maria
  • Pons, Mònica
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Minguez, Beatriz
Biomarkers; Hepatocellular carcinoma; Immunotherapy, Biomarcadors; Carcinoma hepatocel·lular; Immunoteràpia, Biomarcadores; Carcinoma hepatocelular; Inmunoterapia, Immunotherapy has improved survival in patients with advanced hepatocellular carcinoma (HCC); yet, objective radiological responses occur in only about 20% of cases, suggesting variable benefits. This study aimed to identify serologic markers predictive of response to immune checkpoint inhibitors (ICIs). A cohort of 38 advanced HCC patients receiving immunotherapy was prospectively analyzed. Levels of cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and cytokines were measured pre-treatment and three months post-treatment initiation. Genomic profiling of ctDNA was also conducted. Baseline levels of cfDNA and ctDNA effectively discriminated HCC patients based on their radiological response to ICIs. Additionally, individuals with pathologic mutations in the CDKN2A gene exhibited significantly reduced survival. Patients with progressive disease (PD) as their best radiological response had significantly fewer copy number variations (CNVs) than those with a radiological response. Furthermore, levels of IL10, PD1, and TGFβ assessed after three months of treatment showed significant variations correlating with survival status. In conclusion, the analysis of cfDNA, ctDNA, and cytokines may improve treatment selection for HCC patients by predicting their expected response to immunotherapies., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI21/00714 and PI18/00961 to B.M. and co-funded by the European Union. E.V.-A. is a recipient of a predoctoral fellowship from Instituto de Salud Carlos III (ISCIII) (FI18/00027).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Impact of zinc on hepatocellular carcinoma cell behavior and metallothionein expression: Insights from preclinical models

  • Torrens Buscató, Maria
  • Bermúdez-Ramos, Maria
  • Soriano, Agnès
  • Higuera Urbano, Monica
  • Vargas-Accarino, Elena
  • Salcedo, Maria-Teresa
  • Minguez, Beatriz
Carcinoma hepatocel·lular; Zinc; Biomarcador, Hepatocellular carcinoma; Zinc; Biomarker, Carcinoma hepatocelular; Zinc; Biomarcador, Background Zinc (Zn) is an essential trace element involved in a wide variety of cellular processes and is vital for optimal liver function. Our objective was to elucidate the potential therapeutic role of Zn in hepatocellular carcinoma (HCC), the third leading cause of cancer-related death and the first cause of death in patients with cirrhosis. Methods The impact of Zn supplementation on proliferation, invasion, migration, cell cycle, and apoptosis was conducted on four HCC cell lines as well as in a xenograft mouse model of HCC from which tumor gene expression profiles were also analyzed. Gene deregulation and protein expression were validated in human HCC tissues. Finally, Zn and MT1 (Metallothionein 1) levels were quantified in plasma from patients with HCC. Results Zn supplementation significantly modulated proliferation, invasion, and migration in HCC cell lines and induced apoptosis in a dose-dependent manner. Although Zn did not exhibit a significant increase in survival, Zn supplementation significantly altered the expression of MT genes. Specifically, MT1G and MT1H expression were notably suppressed in HCC tissues from mice and these results were validated in human HCC samples. Overall, gene and protein MTs expression was significantly lower in HCC areas compared to adjacent liver tissue and plasma Zn levels exhibited substantial variation across different stages of the liver disease. Conclusion Zn supplementation influences key cellular behaviors in a dose-dependent manner and upregulates the expression of MT family genes, which may have tumor-suppressive properties, in vitro an in vivo models. Future research should investigate the prognostic implications of Zn supplementation as part of a comprehensive therapeutic strategy for HCC patients., This work has been funded by a research grant from Laboratorios Viñas. BM is supported by competitive funding by Instituto de Salud Carlos III (ISCIII) (PI18/00961 and PI21/00714) and co-funded by the European Union.